HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
